CARDIONOVUM
Next-Gen Treatment for Coronary and Peripheral Artery Disease

The field of interventional cardiology witnessed a revolutionary change with the introduction of drug-eluting stents (DES). However, DES technology is known to cause complications, which, although rare, have some long-term effects, most notably in the case of in-stent restenosis and stent thrombosis. At this medical juncture, drug-coated balloons (DCB) emerged as the solution of choice. Based on a leave-nothing-behind concept, DCB treatments do not have the limitations common with DES, such as stent thrombosis and long-term dual antiplatelet therapy (DAPT). The coronary and peripheral artery disease market has hugely benefitted from minimally invasive techniques, with the use of coronary DCB trending in a wider range of indications.

Spearheading this ongoing trend is CARDIONOVUM, a pioneer in cardiovascular medical solutions. CARDIONOVUM develops and commercializes top of the edge medical devices, most notably the new generation of DCB and drug-eluting stents (DES) to treat coronary and peripheral artery disease. “At CARDIONOVUM, we focus our efforts on providing solutions for health care organizations to solve their daily challenges in the treatment of cardiovascular diseases,” says Miquel Craven-Bartle Capella, CEO of CARDIONOVUM.

The company’s state-of-art portfolio of solutions for coronary disease includes XLIMUS, a sirolimus-eluting coronary stent system, and RESTORE DCB, a paclitaxel-releasing coronary balloon dilatation catheter. CARDIONOVUM offers an equally impressive selection for peripheral disease treatment, where LEGFLOW, a paclitaxelreleasing peripheral balloon dilatation catheter, is designed to treat lesions in the Iliac, superficial femoral artery, and below-the-knee artery. Another of the company’s solutions for treating peripheral disease is APERTO, a paclitaxel-releasing hemodialysis shunt balloon dilatation catheter. Always on the lookout for breakthroughs to make better products and technologies, CARDIONOVUM’s introduction of APERTO, the first highpressure coated DCB for treating arteriovenous (AV) fistula, has helped over 5000 patients worldwide.

Deeply committed to clinical research, CARDIONOVUM has developed a disruptive and revolutionary patented coating technology named SAFEPAX, poised to be the next generation of DCB due to its unique features. Present in CARDIONOVUM’s entire range of DCBs, SAFEPAX is based on a non-crystalline coating that has proved outstanding clinical results over the last four years and has the lowest wash-off rate available in the market with optimal drug delivery. With a growing assortment of groundbreaking medical devices, the company provides the necessary training for the techniques and devices to guarantee the best possible results for patients. The training of health care professionals is structured through CARDIONOVUM UNIVERSITY, a tailor-made educational program where physicians of different levels exchange real-life experiences. CARDIONOVUM’s solution APERTO is an important focus area for the university. “CARDIONOVUM is leading the exchange of knowledge in the creation, maintenance and rescue of AV fistula, which has a direct relation with patients’ life expectancy,” says Mr. Craven- Bartle.

Through its network established in over 62 markets, CARDIONOVUM combines its innovative products and makes them available worldwide. This falls right in line with the present consolidation of the cardiovascular medical devices industry, which may lead to a decrease in service level, where the CARDIONOVUM network seeks to offer 24/7 service and tailor-made solutions.

With its sights set on the bigger picture, CARDIONOVUM is expanding its global footprint while extending its reach to therapy coverage. The company aims to be the European company of reference in the cardiovascular space in the next decade. As an innovator of cardiovascular medical solutions, CARDIONOVUM endeavors to be recognized as a leader in technology and service that provides outstanding solutions either through in-house development or acquisitions.

Following our claim, ‘Life deserves the best,’ we would like to reinforce our commitment to improving patients’ quality of life by launching the best medical solutions,” concludes Mr. Craven-Bartle.